Calliditas Therapeutics AB aims to have a US NASDAQ listing in time for a scheduled Phase III readout assessing its lead asset as a first-in-class treatment for inflammatory renal disease IgA nephropathy (IgAN), an orphan chronic autoimmune disease, the Swedish specialty pharma’s CEO told Scrip.
‘Follow The Money’: Sweden’s Calliditas Plans US Listing
CEO Says NASDAQ Float Will Position Biotech Better Before Pivotal Readout
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.
More from Business
• By
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
• By
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.